• Ann D Cohen, Susan M Landau, Beth E Snitz, William E Klunk, Kaj Blennow, and Henrik Zetterberg.
• Department of Psychiatry, University of Pittsburgh School of Medicine, United States of America. Electronic address: cohenad@upmc.edu.
• Mol. Cell. Neurosci. 2019 Jun 1; 97: 3-17.

AbstractAlzheimer's disease (AD) is characterized by amyloid plaques and tau pathology (neurofibrillary tangles and neuropil threads). Amyloid plaques are primarily composed of aggregated and oligomeric β-amyloid (Aβ) peptides ending at position 42 (Aβ42). The development of fluid and PET biomarkers for Alzheimer's disease (AD), has allowed for detection of Aβ pathology in vivo and marks a major advancement in understanding the role of Aβ in Alzheimer's disease (AD). In the recent National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework, AD is defined by the underlying pathology as measured in patients during life by biomarkers (Jack et al., 2018), while clinical symptoms are used for staging of the disease. Therefore, sensitive, specific and robust biomarkers to identify brain amyloidosis are central in AD research. Here, we discuss fluid and PET biomarkers for Aβ and their application.Copyright © 2018 Elsevier Inc. All rights reserved.

25 keywords...

hide…